Eureka Therapeutics, Inc.

Numerous attempts to make CAR-Ts work in solid tumors have failed in recent years, but AstraZeneca has caught attention this week with promising Phase I data for its candidate, C-CAR031 (AZD7003), p

The volume of $100m-plus venture capital mega-rounds continues to build throughout 2023 after a slow start, but a wider look at the biopharmaceutical VC landscape illustrates the valley of death that

The pace of cancer partnering between the biopharma industry and academic and institutional research entities during the final months of 2022 remained typically brisk, and two US institutions – The U

The biopharmaceutical industry cheered Third Harmonic Bio ’s sizeable initial public offering in mid-September but the IPO market in the US has gone quiet since then as broader stock indices – includ